SILK ROAD MEDICAL INC (SILK) Fundamental Analysis & Valuation

NASDAQ:SILK • US82710M1009

27.49 USD
-0.01 (-0.04%)
At close: Sep 16, 2024
27.49 USD
0 (0%)
After Hours: 9/16/2024, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SILK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

SILK gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. The financial health of SILK is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SILK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. SILK Profitability Analysis

1.1 Basic Checks

  • In the past year SILK has reported negative net income.
  • SILK had a negative operating cash flow in the past year.
  • In the past 5 years SILK always reported negative net income.
  • SILK had a negative operating cash flow in each of the past 5 years.
SILK Yearly Net Income VS EBIT VS OCF VS FCFSILK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

  • The Return On Assets of SILK (-20.96%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -36.55%, SILK is in line with its industry, outperforming 54.01% of the companies in the same industry.
Industry RankSector Rank
ROA -20.96%
ROE -36.55%
ROIC N/A
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
SILK Yearly ROA, ROE, ROICSILK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

  • SILK's Gross Margin of 74.28% is amongst the best of the industry. SILK outperforms 85.03% of its industry peers.
  • In the last couple of years the Gross Margin of SILK has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for SILK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
SILK Yearly Profit, Operating, Gross MarginsSILK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SILK Health Analysis

2.1 Basic Checks

  • SILK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SILK has been increased compared to 1 year ago.
  • Compared to 1 year ago, SILK has a worse debt to assets ratio.
SILK Yearly Shares OutstandingSILK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SILK Yearly Total Debt VS Total AssetsSILK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 4.49 indicates that SILK is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.49, SILK is doing good in the industry, outperforming 72.73% of the companies in the same industry.
  • SILK has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
  • SILK's Debt to Equity ratio of 0.49 is on the low side compared to the rest of the industry. SILK is outperformed by 64.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z 4.49
ROIC/WACCN/A
WACC8.47%
SILK Yearly LT Debt VS Equity VS FCFSILK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 7.63 indicates that SILK has no problem at all paying its short term obligations.
  • SILK has a better Current ratio (7.63) than 85.56% of its industry peers.
  • SILK has a Quick Ratio of 6.69. This indicates that SILK is financially healthy and has no problem in meeting its short term obligations.
  • SILK's Quick ratio of 6.69 is amongst the best of the industry. SILK outperforms 83.96% of its industry peers.
Industry RankSector Rank
Current Ratio 7.63
Quick Ratio 6.69
SILK Yearly Current Assets VS Current LiabilitesSILK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. SILK Growth Analysis

3.1 Past

  • The earnings per share for SILK have decreased by -2.13% in the last year.
  • Looking at the last year, SILK shows a quite strong growth in Revenue. The Revenue has grown by 17.54% in the last year.
  • Measured over the past years, SILK shows a very strong growth in Revenue. The Revenue has been growing by 38.63% on average per year.
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.87% on average over the next years.
  • The Revenue is expected to grow by 13.50% on average over the next years. This is quite good.
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SILK Yearly Revenue VS EstimatesSILK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
SILK Yearly EPS VS EstimatesSILK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. SILK Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SILK. In the last year negative earnings were reported.
  • Also next year SILK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SILK Price Earnings VS Forward Price EarningsSILK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SILK Per share dataSILK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.37%
EPS Next 3Y3.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SILK Dividend Analysis

5.1 Amount

  • SILK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SILK Fundamentals: All Metrics, Ratios and Statistics

SILK ROAD MEDICAL INC

NASDAQ:SILK (9/16/2024, 8:00:02 PM)

After market: 27.49 0 (0%)

27.49

-0.01 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07
Earnings (Next)11-06
Inst Owners3.3%
Inst Owner Change0%
Ins Owners28.49%
Ins Owner Change0%
Market Cap1.12B
Revenue(TTM)191.44M
Net Income(TTM)-56.54M
Analysts49.23
Price Target22.54 (-18.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.36%
Min EPS beat(2)-9.6%
Max EPS beat(2)12.31%
EPS beat(4)3
Avg EPS beat(4)8.54%
Min EPS beat(4)-9.6%
Max EPS beat(4)23.2%
EPS beat(8)6
Avg EPS beat(8)10.47%
EPS beat(12)7
Avg EPS beat(12)1.66%
EPS beat(16)9
Avg EPS beat(16)-1.22%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)1.28%
Max Revenue beat(2)6.4%
Revenue beat(4)3
Avg Revenue beat(4)3.97%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)10.41%
Revenue beat(8)6
Avg Revenue beat(8)3.67%
Revenue beat(12)9
Avg Revenue beat(12)2.91%
Revenue beat(16)12
Avg Revenue beat(16)2.27%
PT rev (1m)-2.14%
PT rev (3m)6.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.92%
EPS NY rev (1m)-2.69%
EPS NY rev (3m)-2.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.22%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)1.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.83
P/FCF N/A
P/OCF N/A
P/B 7.22
P/tB 7.22
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS4.71
BVpS3.81
TBVpS3.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.96%
ROE -36.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.28%
FCFM N/A
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.1%
Cap/Sales 1.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.63
Quick Ratio 6.69
Altman-Z 4.49
F-Score4
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)251.08%
Cap/Depr(5y)187.13%
Cap/Sales(3y)3.05%
Cap/Sales(5y)2.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%
EBIT growth 1Y-13.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.12%
EBIT Next 3Y19.7%
EBIT Next 5YN/A
FCF growth 1Y27.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.14%
OCF growth 3YN/A
OCF growth 5YN/A

SILK ROAD MEDICAL INC / SILK FAQ

What is the fundamental rating for SILK stock?

ChartMill assigns a fundamental rating of 3 / 10 to SILK.


Can you provide the valuation status for SILK ROAD MEDICAL INC?

ChartMill assigns a valuation rating of 0 / 10 to SILK ROAD MEDICAL INC (SILK). This can be considered as Overvalued.


What is the profitability of SILK stock?

SILK ROAD MEDICAL INC (SILK) has a profitability rating of 2 / 10.


Can you provide the financial health for SILK stock?

The financial health rating of SILK ROAD MEDICAL INC (SILK) is 5 / 10.